Anticoccidial Drugs Global Market Report 2024

The anticoccidial drugs market size has grown strongly in recent years. It will grow from $1.19 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increased adoption of pet animals, increased incidence of coccidiosis globally, economic impact, high prevalence of coccidiosis, and increased safety concerns about food and health of animals.

The anticoccidial drugs market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth projected for the forecast period can be credited to several factors including the expanding veterinary healthcare sector, the escalating incidence of coccidiosis among animals, the uptick in synthetic drug usage, the rising need for feed additives, and the continuous expansion of livestock production. Notable trends expected in this period encompass increased demand spurred by emerging coccidiosis strains, a transition towards natural and alternative treatment approaches, heightened regulatory oversight prompting innovation, growing consumer preferences for antibiotic-free poultry items, advancements in drug delivery methods, an increased emphasis on preventive healthcare measures, and broader applications in aquaculture and the companion animal industries.

The anticipated surge in demand for meat proteins is poised to drive the expansion of the anticoccidial drug market in the foreseeable future. Meat proteins, integral components of animal flesh, encompass essential amino acids vital for diverse bodily functions. This increased demand for meat proteins stems from factors such as population expansion, rising disposable incomes, urbanization, and shifting dietary preferences favoring protein-rich foods. Anticoccidial drugs play a crucial role in contemporary livestock management practices, ensuring the health and productivity of animals. By leveraging these medications, farmers can effectively and sustainably meet the escalating demand for meat proteins. For example, as per a July 2021 report jointly published by the Organization for Economic Co-operation and Development (OECD) and the Food and Agriculture Organization (FAO), global consumption of meat proteins is projected to increase by 14% by 2030. The report forecasts growth in protein availability from various meat sources, with beef anticipated to rise by 5.9%, pork by 13.1%, poultry by 17.8%, and sheep meat by 15.7%. Thus, the growing demand for meat proteins serves as a catalyst for the expansion of the anticoccidial drug market.

The upsurge in poultry farming is poised to drive the advancement of the anticoccidial drug market in the coming years. Poultry farming involves the rearing of domesticated avian species such as chickens, turkeys, ducks, and geese for the production of meat, eggs, and feathers. This increase in poultry farming is attributed to a growing demand for protein, enhancements in farming methodologies, and the expansion of global trade. Anticoccidial drugs are commonly administered to poultry either through feed or water as a preemptive measure to shield the birds from coccidiosis during their initial and most susceptible growth stages. For instance, as reported by the USDA Economic Research Service in June 2023, total sales in the poultry sector soared to $76.9 billion in 2022, marking a notable 67% surge from the preceding year. Hence, the surge in poultry farming acts as a catalyst for the burgeoning growth of the anticoccidial drug market.

Key players in the anticoccidial drugs market prioritize the development of pioneering solutions, such as those based on zoalene, to enhance effectiveness, mitigate the development of resistance, and tackle emerging poultry and livestock management challenges. Zoalene-based solutions incorporate zoalene as their active component and are employed to combat coccidiosis in poultry. For example, in May 2021, Elanco Animal Health Incorporated, a US-based pharmaceutical firm, launched ZoaShielda, a zoalene-based solution engineered to effectively manage coccidiosis in poultry. This product offers poultry producers a versatile and dependable solution suitable for diverse seasons and operations, ensuring the anticipated efficacy in coccidiosis management while providing operational adaptability to producers.

Major companies operating in the anticoccidial drugs market are Johnson & Johnson, Merck and Co. Inc, Bayer AG, Novartis AG, Eli Lilly and Company Ltd, Boehringer Ingelheim GmbH, Zoetis Inc., Elanco Animal Health Incorporated, Intas Pharmaceuticals Ltd., Ceva Santé Animale S.A., Virbac S.A., Phibro Animal Health Corporation, Vetoquinol SA, Alpharma BVBA, Kepro B.V., Kemin Industries Inc, Tianjin Ringpu Bio-Technology Co. Ltd., Hester Biosciences Limited, Huvepharma AD, Biovet S.A., Lallemand Animal Nutrition, HIPRA, Impextraco NV, Venkateshwara Hatcheries Pvt Ltd.

North America was the largest region in the anticoccidial drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anticoccidial drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anticoccidial drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anticoccidial drugs constitute a category of medications employed in the prevention and treatment of coccidiosis, an intestinal parasitic ailment induced by protozoa from the genus Eimeria. These medications function by impeding diverse stages of the coccidia life cycle, thereby managing the infection and averting the consequential intestinal harm and associated symptoms. Widely utilized in veterinary practice, especially in poultry, these drugs contribute to bolstering health and productivity by addressing this prevalent and economically impactful condition.

The primary categories of anticoccidial drugs encompass ionophores, antibiotics, sulphonamides, chemical derivatives, and others. Ionophores, for instance, intervene in the proliferation and propagation of coccidia parasites by modulating ion movement across cellular membranes. These drugs exhibit varied actions, serving both coccidiostatic and coccidiocidal purposes across diverse applications such as poultry, swine, fish, cattle, and companion animals. They are distributed through various channels, including veterinary hospitals, retail pharmacies, among others.

The anticoccidial drugs market research report is one of a series of new reports that provides anticoccidial drugs market statistics, including anticoccidial drugs industry global market size, regional shares, competitors with a anticoccidial drugs market share, detailed anticoccidial drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anticoccidial drugs industry. This anticoccidial drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoccidial drugs market consist of sales of monensin, semduramicin, lasalocid, decoquinate, salinomycin, amprolium, clopidol, and sulfachloropyrazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.